RxDoctor Payments Data

Shelly Cambell

Family · Boca Raton, FLNPI 1508938515

Payments from drug & device makers

$873in general payments, 2019–2025

Across 36 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$140
  • Novo Nordisk$114
  • Urgo Medical North America, LLC$106
  • Novartis$105
  • GSK$102
  • AbbVie$83
  • plus $223 from 8 others

What the payments were for

  • Food & beverage$78390%
  • Education$9010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$873 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$148,867
Medicare patients
546
Services billed
2,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$40,218
MounjaroTirzepatide14$12,543
MyrbetriqMirabegron13$9,845
Lagevrio (Eua)Molnupiravir24$8,381
SynthroidLevothyroxine Sodium39$3,753
Atorvastatin Calcium305$2,819
Levothyroxine Sodium214$2,148
Rosuvastatin Calcium121$1,788
Gabapentin96$1,707
Losartan Potassium126$1,513
Amlodipine Besylate196$1,459
Pantoprazole Sodium111$1,443
Escitalopram Oxalate84$1,440
Albuterol Sulfate HfaAlbuterol Sulfate47$1,280
Omeprazole77$1,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$40,21831 claims
Lilly USA, LLCMounjaro$19$12,54314 claims
Astellas Pharma US IncMyrbetriq$140$9,84513 claims
AbbVieSynthroid$83$3,75339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →